Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
29 01 2021
Historique:
received: 14 07 2020
accepted: 17 12 2020
entrez: 30 1 2021
pubmed: 31 1 2021
medline: 20 2 2021
Statut: epublish

Résumé

The evolution of DNA methylome and methylation intra-tumor heterogeneity (ITH) during early carcinogenesis of lung adenocarcinoma has not been systematically studied. We perform reduced representation bisulfite sequencing of invasive lung adenocarcinoma and its precursors, atypical adenomatous hyperplasia, adenocarcinoma in situ and minimally invasive adenocarcinoma. We observe gradual increase of methylation aberrations and significantly higher level of methylation ITH in later-stage lesions. The phylogenetic patterns inferred from methylation aberrations resemble those based on somatic mutations suggesting parallel methylation and genetic evolution. De-convolution reveal higher ratio of T regulatory cells (Tregs) versus CD8 + T cells in later-stage diseases, implying progressive immunosuppression with neoplastic progression. Furthermore, increased global hypomethylation is associated with higher mutation burden, copy number variation burden and AI burden as well as higher Treg/CD8 ratio, highlighting the potential impact of methylation on chromosomal instability, mutagenesis and tumor immune microenvironment during early carcinogenesis of lung adenocarcinomas.

Identifiants

pubmed: 33514726
doi: 10.1038/s41467-021-20907-z
pii: 10.1038/s41467-021-20907-z
pmc: PMC7846738
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

687

Subventions

Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234629
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA214195
Pays : United States

Références

PLoS One. 2011;6(6):e21443
pubmed: 21731750
PLoS Genet. 2014 Feb 13;10(2):e1004143
pubmed: 24550741
J Thorac Imaging. 2012 Nov;27(6):340-53
pubmed: 23086014
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Nat Genet. 2007 Feb;39(2):157-8
pubmed: 17200673
PLoS Genet. 2011 Jun;7(6):e1002090
pubmed: 21655081
Bioinformatics. 2015 Apr 1;31(7):1127-9
pubmed: 25417204
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
pubmed: 19458158
Cancer Res. 2017 Nov 15;77(22):6119-6130
pubmed: 28951454
J Thorac Oncol. 2013 Sep;8(9):1163-9
pubmed: 23945386
Nucleic Acids Res. 2013 Sep;41(16):e155
pubmed: 23828043
Cancer Cell. 2013 May 13;23(5):567-9
pubmed: 23680143
Nat Commun. 2020 Jan 30;11(1):603
pubmed: 32001676
Cancer Discov. 2017 Oct;7(10):1088-1097
pubmed: 28733428
Cell Rep. 2018 Oct 23;25(4):1066-1080.e8
pubmed: 30355485
Dis Markers. 2007;23(1-2):5-30
pubmed: 17325423
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4828-33
pubmed: 19261858
Clin Cancer Res. 2010 Apr 15;16(8):2418-26
pubmed: 20371677
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Science. 2014 Oct 10;346(6206):256-9
pubmed: 25301631
J Pathol. 2017 Jan;241(1):10-24
pubmed: 27770445
Oncogene. 2002 Dec 5;21(55):8470-6
pubmed: 12466966
Nature. 1998 Sep 3;395(6697):89-93
pubmed: 9738504
Ther Clin Risk Manag. 2018 Jan 31;14:203-211
pubmed: 29430182
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Science. 2017 May 5;356(6337):
pubmed: 28473536
Mol Cancer. 2017 Feb 16;16(1):41
pubmed: 28209166
Crit Rev Oncol Hematol. 2018 Jan;121:23-44
pubmed: 29279097
Nat Commun. 2016 Oct 21;7:13200
pubmed: 27767028
Cell Death Differ. 2016 Feb;23(2):207-15
pubmed: 26113043
Bioinformatics. 2016 Feb 15;32(4):587-9
pubmed: 26508757
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Nat Genet. 2007 Feb;39(2):237-42
pubmed: 17211412
Clin Cancer Res. 2018 Dec 15;24(24):6195-6203
pubmed: 30228210
Nat Rev Urol. 2017 Oct;14(10):575-576
pubmed: 28720862
Cancer Prev Res (Phila). 2011 Jun;4(6):787-92
pubmed: 21636545
Cells. 2019 Mar 21;8(3):
pubmed: 30901978
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14631-6
pubmed: 25246589
Am J Transl Res. 2019 Aug 15;11(8):5039-5053
pubmed: 31497220
Nucleic Acids Res. 2018 Nov 2;46(19):e114
pubmed: 29986099
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Nat Genet. 2012 Nov;44(11):1207-14
pubmed: 23064413
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Blood. 2018 May 3;131(18):2007-2015
pubmed: 29514782
Nat Commun. 2018 Aug 13;9(1):3220
pubmed: 30104673
Nat Protoc. 2011 Apr;6(4):468-81
pubmed: 21412275
Nat Genet. 2007 Feb;39(2):232-6
pubmed: 17200670
Cancer Cell Int. 2018 Apr 10;18:56
pubmed: 29651226
Nat Commun. 2019 Jul 5;10(1):2978
pubmed: 31278276
Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97
pubmed: 20947487
Bioinformatics. 2019 Sep 15;35(18):3287-3293
pubmed: 30726880
Nat Commun. 2019 Nov 29;10(1):5472
pubmed: 31784532
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Oncotarget. 2017 Mar 28;8(13):21994-22002
pubmed: 28423542
Science. 2003 Apr 18;300(5618):455
pubmed: 12702868
Nat Commun. 2019 Sep 19;10(1):4278
pubmed: 31537801
Genome Biol. 2012 Oct 03;13(10):R87
pubmed: 23034086
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880
pubmed: 32274301
Bioinformatics. 2015 Jul 15;31(14):2382-3
pubmed: 25765347
Science. 2017 Jul 21;357(6348):
pubmed: 28729483
Nat Genet. 2008 Jun;40(6):741-50
pubmed: 18488029
Genome Biol. 2014 Sep 27;15(9):472
pubmed: 25260792
Genome Biol. 2018 Sep 28;19(1):150
pubmed: 30266094
Nat Genet. 2011 Jun 26;43(8):768-75
pubmed: 21706001
Cancer Cell. 2014 Dec 8;26(6):813-825
pubmed: 25490447
Genome Res. 2012 Feb;22(2):246-58
pubmed: 22156296
Nat Commun. 2020 May 18;11(1):2459
pubmed: 32424208
Sci Transl Med. 2013 Jan 23;5(169):169ra10
pubmed: 23345608
Cancer Prev Res (Phila). 2016 Jul;9(7):518-27
pubmed: 27006378
Nat Protoc. 2017 Dec;12(12):2478-2492
pubmed: 29120462

Auteurs

Xin Hu (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Marcos R Estecio (MR)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Center of Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Runzhe Chen (R)

Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Alexandre Reuben (A)

Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Linghua Wang (L)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Junya Fujimoto (J)

Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Jian Carrot-Zhang (J)

Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
Harvard Medical School, Boston, MA, 02115, USA.

Nicholas McGranahan (N)

Cancer Research United Kingdom-University College London Lung Cancer Centre of Excellence, London, SW73RP, UK.

Lisha Ying (L)

Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, 310022, Hangzhou, China.
Zhejiang Cancer Research Institute, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), 310022, Hangzhou, China.

Junya Fukuoka (J)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 8528523, Japan.

Chi-Wan Chow (CW)

Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Hoa H N Pham (HHN)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 8528523, Japan.

Myrna C B Godoy (MCB)

Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Brett W Carter (BW)

Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Carmen Behrens (C)

Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Jianhua Zhang (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Mara B Antonoff (MB)

Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Boris Sepesi (B)

Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Yue Lu (Y)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Center of Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Harvey I Pass (HI)

Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, NY, 10016, USA.

Humam Kadara (H)

Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Paul Scheet (P)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Ara A Vaporciyan (AA)

Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

John V Heymach (JV)

Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Ignacio I Wistuba (II)

Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

J Jack Lee (JJ)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

P Andrew Futreal (PA)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. afutreal@mdanderson.org.

Dan Su (D)

Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), 310022, Hangzhou, China. sudan@zjcc.org.cn.

Jean-Pierre J Issa (JJ)

Coriell Institute for Medical Research, Camden, NJ, 08103, USA. jpissa@coriell.org.

Jianjun Zhang (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org.
Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH